Alok Pandey
Research Subjects
Alok Pandey has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Hays
BioAgilytix Labs
2 shared publications - Carmen Fernández-Metzler
PharmaCadence Analytical Services, LLC
2 shared publications - Jennifer Green
Takeda Development Center Americas, Inc
2 shared publications - Karen J. Quadrini
Prothena Biosciences Inc, Brisbane, CA 94005, USA
2 shared publications - Lakshmi Amaravadi
AstraZeneca, Waltham, USA
2 shared publications - Mohamed Hassanein
Translational and Clinical Biomarkers, Pfizer Inc. Pearl River New York USA
2 shared publications
Latest Publications
- 2 January 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (1) , 91-109
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.
- 2 January 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (1) , 91-109
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.
- Open Access
- 30 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-4
Why is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?
- 30 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-4
Open AccessWhy is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?